Oppenheimer Terminates Relypsa Inc(NASDAQ:RLYP)

Brokerage firm Oppenheimer Terminates its rating on Relypsa Inc(NASDAQ:RLYP). Previously, the analysts had a Outperform rating on the shares. The rating by Oppenheimer was issued on Aug 9, 2016.

In a different note, On Jul 26, 2016, Guggenheim Securities said it Downgrades its rating on Relypsa Inc. The shares have been rated ‘Hold’ by the firm. On Jul 26, 2016, Cantor Fitzgerald said it Downgrades its rating on Relypsa Inc. The shares have been rated ‘Hold’ by the firm. On Jul 25, 2016, Guggenheim Securities said it Downgrades its rating on Relypsa Inc. The shares have been rated ‘Sell’ by the firm. On Jul 22, 2016, H.C. Wainwright said it Downgrades its rating on Relypsa Inc. The shares have been rated ‘Neutral’ by the firm. On Jul 22, 2016, Morgan Stanley said it Downgrades its rating on Relypsa Inc. The shares have been rated ‘Equal-weight’ by the firm. On Jul 21, 2016, Morgan Stanley said it Upgrades its rating on Relypsa Inc. In the research note, the firm Raises the price-target to $9.00 per share. The shares have been rated ‘Equal-weight’ by the firm.

Relypsa Inc (RLYP) remained unchanged at the close of Wednesday session. Even as the volume increased to 14,47,999 ,the shares failed to make any impression and ended at 0 points or 0.00% at $31.91. The trading session commenced at $31.93 and the stock hit a high of $31.93 and touched $31.91 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $32.12 and the 52-week low is $10.26. The company has a market cap of $1,432 M and has approximately 4,48,82,597 outstanding shares.

Relypsa Inc(RLYP) last announced its earnings results on Aug 5, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.22M. Analysts had an estimated revenue of $5.45M. Earnings per share were $-1.87. Analysts had estimated an EPS of $-1.56.

Several Insider Transactions has been reported to the SEC. On Jun 8, 2016, Helen Torley (director) sold 1,013 shares at $19.32 per share price.Also, On Jun 8, 2016, Daniel K Spiegelman (director) sold 1,013 shares at $19.31 per share price.On Jun 8, 2016, Kenneth J. Hillan (director) sold 1,013 shares at $19.31 per share price, according to the Form-4 filing with the securities and exchange commission.

Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *